Oncolytic Virotherapy for Hematological Malignancies by Swarna Bais, Eric Bartee, Masmudur M. Rahman, Grant McFadden, Christopher R. Cogle

“…Hematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes (MDSs) primarily affect adults and are difficult to treat. …”
Get full text

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy by Pradyumna Agasthi, Hemalatha Narayanasamy, Dan Sorajja, James Slack, Farouk Mookadam

Get full text

Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies by William A. Fabricius, Muthalagu Ramanathan

Get full text

Ulcerative Colitis in Hematological Malignancies: Paraneoplastic Manifestation or Coincidental Bystander? by Gregorios Christodoulidis, Konstantinos Perivoliotis, Anastasios Manolakis, Alexandros Diamantis, Apostolos Koffas, Dimitrios Magouliotis, Vasiliki Pappi, Dimitrios Zacharoulis

“…Evidence of coexistence of diverse hematological malignancies—lymphoma, leukemia, multiple myeloma, and myelodysplastic syndromes—and either ulcerative colitis or Crohn’s disease can be found in the literature. …”
Get full text

Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies by Junko Okabe-Kado, Takashi Kasukabe, Yasuhiko Kaneko

“…An elevated serum level of NM23-H1 protein is a poor prognostic factor in patients with various hematologic malignancies. The extracellular NM23-H1 protein promotes the in vitro growth and survival of acute myelogenous leukemia (AML) cells and inversely inhibits the in vitro survival of normal peripheral blood monocytes in primary culture at concentrations equivalent to the levels found in the serum of AML patients. …”
Get full text

Frequency and Treatment Outcome of Invasive Fungal Infections in Children with Hematological Malignancies by Rabiha Manzoor, Rabia Tariq, Awais Arshed, Qurat Ul Ain Ali, Ajaz Ahmed, Fozia Sayed Rasool

“…Conclusion: The frequency of IFS was 17.1% among children with hematological malignancies. Mortality was relatively high (24.4%) among children with IFIs which warrants early identification and treatment of IFIs among children with hematological malignancies. …”
Get full text

ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives by Marco Folci, Giacomo Ramponi, Dana Shiffer, Aurora Zumbo, Michele Agosti, Enrico Brunetta

“…Paraneoplastic AAV seems to be an uncommon presentation of hemopathies. Hematologic malignancy risk in AAV is more likely to be increased by cyclophosphamide, although not yet definitely proven. …”
Get full text

Infiltrative Lung Diseases: Complications of Novel Antineoplastic Agents in Patients with Hematological Malignancies by Bobbak Vahid, Paul E Marik

“…Infiltrative lung disease is a well-known complication of antineoplastic agents in patients with hematological malignancies. Novel agents are constantly being added to available treatments. …”
Get full text

Serum Voriconazole Level Variability in Patients with Hematological Malignancies Receiving Voriconazole Therapy by Lalit Saini, Jack T Seki, Deepali Kumar, Eshetu G Atenafu, David EC Cole, Betty YL Wong, Andrea Božović, Joseph M Brandwein

“…INTRODUCTION: Voriconazole plasma concentrations have been correlated with oral dosing in healthy subjects, but have been poorly characterized in ill patients with hematological malignancies receiving intensive chemotherapy.…”
Get full text

BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies by Mariam Markouli, Maria N. Pagoni, Panagiotis Diamantopoulos

Get full text

Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies by Cui Y, Liu X, Feng S

Subjects: “…hematological malignancy…”
Get full text

Anticancer Role of PPARγ Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes by P. J. Simpson-Haidaris, S. J. Pollock, S. Ramon, N. Guo, C. F. Woeller, S. E. Feldon, R. P. Phipps

“…This paper has two objectives: first to highlight the potential uses for PPARγ agonists in anticancer therapy with special emphasis on their role when used as adjuvant or combined therapy in the treatment of hematological malignancies found in the vasculature, marrow, and eyes, and second, to review the potential role PPARγ and/or its ligands may have in modulating cancer-associated angiogenesis and tumor-stromal microenvironment crosstalk in bone marrow.…”
Get full text

Role of Peroxisome Proliferator-Activated Receptor Gamma and Its Ligands in the Treatment of Hematological Malignancies by Richard P. Phipps, <?layout cmd="newline"?> Patricia J. Sime, Steven H. Bernstein, Tatiana M. Garcia-Bates, Geniece M. Lehmann, Patricia J. Simpson-Haidaris

Get full text

Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity by Xiang-mei Wen, Xiang-mei Wen, Xiang-mei Wen, Zi-jun Xu, Zi-jun Xu, Zi-jun Xu, Ji-chun Ma, Ji-chun Ma, Ji-chun Ma, Min-jie Zhang, Min-jie Zhang, Min-jie Zhang, Ye Jin, Ye Jin, Jiang Lin, Jiang Lin, Jiang Lin, Jun Qian, Jun Qian, Yuan-yuan Fang, Yuan-yuan Fang, Yuan-yuan Fang, Shu-yu Luo, Shu-yu Luo, Shu-yu Luo, Zhen-wei Mao

Subjects: Get full text

Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies by Scott Wadler

Get full text

Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies by Ilaria Laurenzana, Daniela Lamorte, Stefania Trino, Luciana De Luca, Concetta Ambrosino, Pietro Zoppoli, Vitalba Ruggieri, Luigi Del Vecchio, Pellegrino Musto, Antonella Caivano, Geppino Falco

“…The bone marrow (BM) microenvironment in hematological malignancies (HMs) comprises heterogeneous populations of neoplastic and nonneoplastic cells. …”
Get full text

Virological Aspects of COVID-19 in Patients with Hematological Malignancies: Duration of Viral Shedding and Genetic Analysis by Asma Themlaoui, Massimo Ancora, Kais Ghedira, Yosra Mhalla, Manel Hamdoun, Maroua Bahri, Lamia Aissaoui, Raihane Ben Lakhal, Adriano Di Pasquale, Cesare Camma, Olfa Bahri

Subjects: “…hematological malignancies…”
Get full text

Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study by Hovav Azuly, Tali Shafat, Daniel Grupel, Tzvika Porges, Ran Abuhasira, Ana Belkin, Ofir Deri, Yonatan Oster, Shadi Zahran, Ehud Horwitz, Netanel A. Horowitz, Hazim Khatib, Marjorie Vieira Batista, Anita Cassoli Cortez, Tal Brosh-Nissimov, Yafit Segman, Linor Ishay, Regev Cohen, Alaa Atamna, Amy Spallone, Roy F. Chemaly, Juan Carlos Ramos, Michal Chowers, Evgeny Rogozin, Noga Carmi Oren, Şiran Keske, Orit Wolfovitz Barchad, Lior Nesher, on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)

Subjects: Get full text

40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies by Kristen Corrao, Adrian Umpierrez, Angela Treml, Aniko Szabo, Laura Michaelis, Lyndsey Runaas, Guru Subramanian Guru Murthy, Sameem Abedin, Karen Carlson, Lisa Baumann Kreuziger, Ehab Atallah

Get full text

Prevalence of platinum-induced ototoxicity among patients suffering from hematological malignancies – a systematic review by Aleksandra Janowiak-Majeranowska, Gazala Abdulaziz-Opiela, Jakub Osowski, Bogusław Mikaszewski

Subjects: Get full text